Non-Small-Cell Lung Cancer | Current Treatment: Physician Insights | EU5 | 2020

The current treatment algorithm for non-small-cell lung cancer (NSCLC) is rapidly evolving. The increasing number of biomarker-driven therapies has resulted in a highly segmented space dominated by branded targeted therapies. In the EGFR-positive setting, Tarceva (Roche) and Giotrif (Boehringer Ingelheim) are facing increasing competition from Tagrisso (AstraZeneca) and Vizimpro (Pfizer). In other key populations, the PD-1 inhibitor Keytruda (Merck & Co.) continues to dominate due to its demonstrated survival benefit. However, novel immune checkpoint inhibitor combinations incorporating Tecentriq (Roche) with Avastin (Roche) and/or chemotherapy will compete and provide alternative treatment options. Our primary research provides insight into the current use of approved therapies for NSCLC in the EU5 and uncovers key factors that influence medical oncologists’ prescribing decisions.

QUESTIONS ANSWERED

What are the treatment rates in the various lines of therapy for metastatic NSCLC?
How are newly approved agents for EGFR-positive (Tagrisso, Vizimpro) and ALK-translocation-positive (Alunbrig, Lorviqua) NSCLC changing the treatment landscape for specific patients?
How are Keytruda- and Tecentriq-based chemotherapy regimens performing in the first-line metastatic NSCLC setting? Which regimen do the EU5 physicians favor? Does it change according to geography?
What are the main obstacles in prescribing immune checkpoint inhibitors (as monotherapies or combination approaches) forNSCLC?

PRODUCT DESCRIPTION

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

Markets covered: France, Germany, Italy, Spain, and the United Kingdom

Primary research: Survey of 50 medical oncologists in each EU5 country.

Key drugs covered: Keytruda, Opdivo, Tecentriq, Imfinzi, Avastin, Tarceva, Iressa, Giotrif, Tagrisso, Vizimpro, Xalkori, Zykadia, Alecensa, Alunbrig, Lorviqua, Tafinlar, Mekinist

Contact sales account_box

Report

Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)

Major depressive disorder (MDD) is a widely drug-treated condition managed with multiple drug classes, most commonly selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine…

north_east

Report

Peripheral Arterial Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Peripheral Artery Disease (US)

Peripheral artery disease (PAD) is a subtype of atherosclerotic cardiovascular disease affecting the arteries of the lower extremities and is associated with reduced walking capacity, claudication…

north_east

Report

Psoriatic Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Psoriatic Arthritis (US)

Treatment of psoriatic arthritis (PsA) typically begins with conventional disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, and progresses to more potent biologics and/or…

north_east

Report

Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms: Claims Data Analysis – IBS-Constipation (including IBS without Diarrhea) (US)

Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by altered bowel motility, stool consistency, and frequency, and is classified into constipation-predominant,…

north_east

Report

Chronic Obstructive Pulmonary Disease – Current Treatment – Current Treatment: Physician Insights – Chronic Obstructive Pulmonary Disease (EU5)

The treatment landscape for chronic obstructive pulmonary disease (COPD) has significantly evolved in the past few years. A plethora of COPD treatments are available in the EU5. These include long-…

north_east

Product logins

Non-Small-Cell Lung Cancer | Current Treatment: Physician Insights | EU5 | 2020

Related Market Assessment Reports

Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)

Peripheral Arterial Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Peripheral Artery Disease (US)

Psoriatic Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Psoriatic Arthritis (US)

Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms: Claims Data Analysis – IBS-Constipation (including IBS without Diarrhea) (US)

Chronic Obstructive Pulmonary Disease – Current Treatment – Current Treatment: Physician Insights – Chronic Obstructive Pulmonary Disease (EU5)

Follow us

Contact us